Health news and commentary gathered by MedPage Today staff ...

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance ...

A new oral version of the weight loss drug Wegovy has been approved by the FDA, offering a more affordable and accessible ...

, a clinical-stage pharmaceutical company developing a novel oral therapy targeting thioredoxin-interacting protein ...

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist (GLP-1) pill is more effective for weight loss than oral ...

With close to one million downloads, Shotsy is the most popular GLP-1 tracking app on the market, and now meets patients at every stage of their GLP-1 journey.

Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

By Danny Callaghan and Bernadette Hogg March 10 (Reuters) - Chocolate sales are rising faster among U.S. users of GLP-1 weight-loss drugs than in the rest of the population, Swiss chocolatier Lindt & ...